PURPOSE: Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. METHODS AND MATERIALS: We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). RESULTS: At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. CONCLUSIONS: Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.
PURPOSE: Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. METHODS AND MATERIALS: We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). RESULTS: At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. CONCLUSIONS: Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.
Authors: Gérard Ganem; Guillaume Cartron; Théodore Girinsky; Rick L M Haas; Jean Marc Cosset; Philippe Solal-Celigny Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-15 Impact factor: 7.038
Authors: S L Stafford; T F Kozelsky; J A Garrity; P J Kurtin; J A Leavitt; J A Martenson; T M Habermann Journal: Radiother Oncol Date: 2001-05 Impact factor: 6.280
Authors: J G Letschert; D González González; J Oskam; L Koornneef; J D van Dijk; R Boukes; J Bras; P van Heerde; H Bartelink Journal: Radiother Oncol Date: 1991-09 Impact factor: 6.280
Authors: Quynh Thu Le; Stephen M Eulau; Tracy I George; Richard Hildebrand; Roger A Warnke; Sarah S Donaldson; Richard T Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-01 Impact factor: 7.038
Authors: Elisa K Chan; Sharon Fung; Mary Gospodarowicz; David Hodgson; Woodrow Wells; Alexander Sun; Melania Pintile; Richard W Tsang Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-16 Impact factor: 7.038
Authors: K J Minehan; J A Martenson; J A Garrity; P J Kurtin; P M Banks; M G Chen; J D Earle Journal: Int J Radiat Oncol Biol Phys Date: 1991-04 Impact factor: 7.038
Authors: R L M Haas; Ph Poortmans; D de Jong; M Verheij; M van der Hulst; J P de Boer; H Bartelink Journal: Eur J Cancer Date: 2005-08 Impact factor: 9.162
Authors: R L M Haas; Ph Poortmans; D de Jong; B M P Aleman; L G H Dewit; M Verheij; A A M Hart; M H J van Oers; M van der Hulst; J W Baars; H Bartelink Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Chelsea C Pinnix; Jillian R Gunther; Sarah A Milgrom; Ruben J Cruz Chamorro; L Jeffrey Medeiros; Joseph D Khoury; Behrang Amini; Sattva Neelapu; Hun J Lee; Jason Westin; Nathan Fowler; Loretta Nastoupil; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-12 Impact factor: 7.038
Authors: Khaled Elsayad; Gabriele Reinartz; Michael Oertel; Stephan Rehn; Jens Eismann; Sergiu Scobioala; Hendrik Berssenbrügge; Nicole Eter; Carsten Weishaupt; Hartmut H Schmidt; Birte Friedrichs; Inga Grünewald; Wolfgang Hartmann; Georg Lenz; Eva Wardelmann; Normann Willich; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2019-11-15 Impact factor: 3.621
Authors: Chelsea C Pinnix; Bouthaina S Dabaja; Sarah A Milgrom; Grace L Smith; Zeinab Abou; Loretta Nastoupil; Jorge Romaguera; Francesco Turturro; Nathan Fowler; Luis Fayad; Jason Westin; Sattva Neelapu; Michelle A Fanale; Maria A Rodriguez; Frederick Hagemeister; Hun Ju Lee; Yasuhiro Oki; Michael Wang; Felipe Samaniego; Linda Chi; Bita Esmaeli Journal: Head Neck Date: 2017-04-03 Impact factor: 3.147
Authors: Jonathan Baron; Christopher M Wright; Daniel Y Lee; Maribel Carpenter; Shwetha H Manjunath; César A Briceño; Elise Chong; Amit Maity; John P Plastaras; Ima Paydar Journal: Front Oncol Date: 2021-07-05 Impact factor: 6.244
Authors: Konstantin V Astafurov; Erick D Bothun; Nadia N Laack; Amanda J Deisher; Sanjay V Patel; Lauren A Dalvin Journal: Am J Ophthalmol Case Rep Date: 2021-05-15